3
Announcements
Trials
Browse
Landscape
Status
Recruiting
5
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
23
Observational
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Dermatologic
1
Conditions
Neoplasms
1
Carcinoma, Basal Cell
1
Interventions
Surveys and Questionnaires
286
Blood Specimen Collection
145
Gene Expression Profiling
96
Interviews as Topic
83
Immunohistochemistry
78
Polymerase Chain Reaction
64
Surgical Procedures, Operative
62
Magnetic Resonance Spectroscopy
58
Microarray Analysis
55
Flow Cytometry
53
Radiotherapy
49
Amplified Fragment Length Polymorphism Analysis
48
Drug Therapy
46
Observation
45
Biopsy
42
Reverse Transcriptase Polymerase Chain Reaction
39
Bevacizumab
39
Data Collection
35
Sorafenib
29
Psychiatric Rehabilitation
29
Nivolumab
28
palbociclib
26
In Situ Hybridization, Fluorescence
26
Rituximab
25
Therapeutics
24
Neoadjuvant Therapy
24
Hepatectomy
24
Docetaxel
24
Colonoscopy
24
Sunitinib
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Observational
×
cemiplimab
×
Clear all
NCT03836105
2025-10-15
CASE
Regeneron Pharmaceuticals
Completed
287 enrolled
NCT05302297
2022-12-13
TOSCA
Sanofi
Completed
305 enrolled